Literature DB >> 20061814

Glutamate receptors in pediatric tumors of the central nervous system.

Katja S Brocke1, Christian Staufner, Hella Luksch, Kathrin D Geiger, Andrzej Stepulak, Jenny Marzahn, Gabriele Schackert, Achim Temme, Chrysanthy Ikonomidou.   

Abstract

Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS). Experimental evidence indicates that glutamate receptor antagonists may limit tumor growth. This study explores expression of glutamate receptor subunits in pediatric CNS tumors. Samples from eight ependymomas, four glioblastomas, six medulloblastomas and eight low grade astrocytomas were analysed. RNA was used for semiquantitative and quantitative RT-PCR. We examined expression of NMDA receptor subunits NR1-NR3B, AMPA receptor subunits GluR1-GluR4, kainate receptor subunits GluR5-GluR7, KA1, KA2 and metabotropic receptor subunits mGluR1-8. Paraffin embedded samples were immunohistochemically stained for selected subunits. All glutamate receptor subunits were differentially expressed in the tumors examined. Expression of NR2D, NR3A, KA1, GluR4, mGluR1, mGluR4, mGluR5 and mGluR6 was higher in the high grade tumors compared to human brain (HB). In low grade astrocytomas expression of glutamate receptor subunits was comparable or lower than in HB. Immunohistochemistry revealed expression of several glutamate receptor subunit proteins in tumor specimen. This study demonstrates expression of glutamate receptor subunits in pediatric CNS tumors. Together with experimental evidence indicating that interference with glutamate signalling may suppress tumor growth, our findings suggest that adjunctive treatment with glutamate receptor modulators may be a feasible therapeutic option for pediatric patients with CNS tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061814     DOI: 10.4161/cbt.9.6.10898

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  32 in total

1.  mGlu Receptors and Cancerous Growth.

Authors:  Jessica Teh; Suzie Chen
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2011-10-25

2.  Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population.

Authors:  Kun Wang; Jinmin Zhao; Maolin He; Mitra Fowdur; Tenglong Jiang; Shuju Luo
Journal:  Tumour Biol       Date:  2015-08-15

3.  PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Dan Li; Hong Shan; Peter Conti; Zibo Li
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

4.  Expression of metabotropic glutamate receptor 4 in osteosarcoma.

Authors:  Shuo Wang; Xing Wei; Bingyao Chen; Min Zhao; Guangze Song; Zengliang Zhang; Nan Li
Journal:  Mol Clin Oncol       Date:  2015-10-23

5.  High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma.

Authors:  Wu Yang; He Maolin; Zhao Jinmin; Wang Zhe
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-08       Impact factor: 4.553

Review 6.  Metabotropic glutamate receptors in cancer.

Authors:  Lumeng J Yu; Brian A Wall; Janet Wangari-Talbot; Suzie Chen
Journal:  Neuropharmacology       Date:  2016-02-16       Impact factor: 5.250

7.  Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice.

Authors:  Kyu Yeong Choi; Kai Chang; James M Pickel; John D Badger; Katherine W Roche
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-06       Impact factor: 11.205

8.  A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

Authors:  Janice M Mehnert; Ann W Silk; J H Lee; Liesel Dudek; Byeong-Seon Jeong; Jiadong Li; Jason M Schenkel; Evita Sadimin; Michael Kane; Hongxia Lin; Weichung J Shih; Andrew Zloza; Suzie Chen; James S Goydos
Journal:  Pigment Cell Melanoma Res       Date:  2018-04-10       Impact factor: 4.693

9.  Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies GRIA1 as a prognostic biomarker for basal-like bladder cancer.

Authors:  Sloane K Tilley; William Y Kim; Rebecca C Fry
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

10.  Noninvasive detection of glutamate predicts survival in pediatric medulloblastoma.

Authors:  Martin Wilson; Simrandip K Gill; Lesley MacPherson; Martin English; Theodoros N Arvanitis; Andrew C Peet
Journal:  Clin Cancer Res       Date:  2014-06-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.